Literature DB >> 23500088

Intestinal perforation in gynecologic oncology: do all patients benefit from surgical management?

Gunjal Garg1, L Stewart Massad, Shabnam Pourabolghasem, Gongfu Zhou, Matthew A Powell, Premal H Thaker, Andrea R Hagemann, Ivy Wilkinson-Ryan, David G Mutch.   

Abstract

OBJECTIVE: To identify those patients with gynecologic cancers and intestinal perforation in whom conservative management may be appropriate.
METHODS: A retrospective review was performed of all gynecologic oncology patients with intestinal perforation at our institution between 1995 and 2011. The Kaplan-Meier method and Cox proportional hazards models were used to analyze factors influencing survival.
RESULTS: Forty-three patients met the study criteria. The mean age was 59 years (range: 38-82 years). A large number of patients had peritoneal carcinomatosis and history of bowel obstruction. Surgery was performed in 28 patients, and 15 were managed conservatively. Overall mortality at 1, 3, 6, and 12 months was 26%, 40%, 47%, and 59%, respectively. Only cancer burden at the time of perforation was independently predictive of mortality. Patients with peritoneal carcinomatosis, distant metastasis, or both were at 42 times higher risk of death than those with no evidence of disease (95% CI: 3.28-639.83), and at 7 times higher risk of death than those with microscopic/localized disease (95% CI: 1.77-29.94). When adjusted for the extent of disease spread, management approach (conservative vs. surgical) was not a significant predictor of survival (p≥0.05). The length of hospital stay (19 days vs. 7 days) and the complication rate (75% vs. 26.7%) were significantly higher in the surgical group than in the non-surgical group (p<0.05).
CONCLUSIONS: Patients who develop intestinal perforation in the setting of widely metastatic disease have a particularly poor prognosis. Aggressive surgical management is unlikely to benefit such patients and further impairs their quality of life.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23500088      PMCID: PMC3992286          DOI: 10.1016/j.ygyno.2013.03.004

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

1.  When death is imminent: where terminally ill patients with cancer prefer to die and why.

Authors:  Siew Tzuh Tang
Journal:  Cancer Nurs       Date:  2003-06       Impact factor: 2.592

2.  Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Authors:  D L Richardson; F J Backes; J D Hurt; L G Seamon; L J Copeland; J M Fowler; D E Cohn; D M O'Malley
Journal:  Gynecol Oncol       Date:  2010-04-10       Impact factor: 5.482

Review 3.  Bevacizumab toxicities and their management in ovarian cancer.

Authors:  Leslie M Randall; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2010-04-02       Impact factor: 5.482

4.  Clinical predictors of bevacizumab-associated gastrointestinal perforation.

Authors:  Janos L Tanyi; Georgia McCann; Andrea R Hagemann; George Coukos; Stephen C Rubin; John B Liao; Christina S Chu
Journal:  Gynecol Oncol       Date:  2010-12-17       Impact factor: 5.482

5.  Sigmoid perforation following radiation therapy in patients with cervical cancer.

Authors:  P T Ramirez; C Levenback; T W Burke; P Eifel; J K Wolf; D M Gershenson
Journal:  Gynecol Oncol       Date:  2001-07       Impact factor: 5.482

6.  Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly.

Authors:  Joseph S Farhat; Vic Velanovich; Anthony J Falvo; H Mathilda Horst; Andrew Swartz; Joe H Patton; Ilan S Rubinfeld
Journal:  J Trauma Acute Care Surg       Date:  2012-06       Impact factor: 3.313

7.  Survival after intestinal perforation: can it be predicted?

Authors:  Celestine S Tung; Charlotte C Sun; Matthew P Schlumbrecht; Larissa A Meyer; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2009-09-18       Impact factor: 5.482

8.  The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.

Authors:  Neil S Horowitz; David E Cohn; Thomas J Herzog; David G Mutch; Janet S Rader; Sanjeev Bhalla; Randall K Gibb
Journal:  Gynecol Oncol       Date:  2002-07       Impact factor: 5.482

9.  Spontaneous free perforation of the small intestine.

Authors:  R D Orringer; J A Coller; M C Veidenheimer
Journal:  Dis Colon Rectum       Date:  1983-05       Impact factor: 4.585

10.  Large bowel perforation: morbidity and mortality.

Authors:  K Bielecki; P Kamiński; M Klukowski
Journal:  Tech Coloproctol       Date:  2002-12       Impact factor: 3.781

View more
  1 in total

1.  Small bowel perforation due to indistinguishable metastasis of angiosarcoma: case report and brief literature review.

Authors:  Tomoyuki Uchihara; Yu Imamura; Shiro Iwagami; Ikko Kajihara; Hisashi Kanemaru; Ryuichi Karashima; Satoshi Ida; Takatsugu Ishimoto; Yoshifumi Baba; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Masayuki Watanabe; Ken-Ichi Iyama; Hironobu Ihn; Hideo Baba
Journal:  Surg Case Rep       Date:  2016-05-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.